Following the company’s receipt of positive clinical data, Leede Jones Gable analyst Douglas L... Read More
Following the release of new preclinical data, Leede Jones Gable analyst Douglas Loe remains upbeat ... Read More
Following news from the company, Leede Jones Gable analyst Douglas Loe remains bullish about Cardiol... Read More
The stock may be down considerably over the past year and a half, but investors can expect better ti... Read More
Leede Jones Gable analyst Douglas W. Loe provided an update to clients on Monday on Canadian cardiov... Read More
With the news of a discontinued clinical trial from Cardiol Therapeutics (Cardiol Therapeutics Stock... Read More
Leede Jones Gable reported on Canadian drug developer Cardiol Therapeutics (Cardiol Therapeutics Sto... Read More
Biotech company Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News, Analysts, Finan... Read More
Shares of communications equipment maker Redline Communications (Redline Communications Stock Quote,... Read More
Shares of retailer Aritzia (Aritzia Stock Quote, Chart, News, Analysts, Financials TSX:ATZ) are topp... Read More
Pharmaceutical companies aren’t every investor’s jam, what with their risk/reward meter at the u... Read More
Raymond James analyst Rahul Sarugaser is increasingly confident in Cardiol Therapeutics (Cardiol The... Read More
With its clinical programs derisked by a new financing round, investors have more reason to buy Card... Read More
With its COVID-19 clinical trial now a go, Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, C... Read More
Look for clinical advances over the first half of 2021 from Cardiol Therapeutics (Cardiol Therapeuti... Read More
Raymond James analyst Rahul Sarugaser has dropped his target and rating on cannabis biopharmaceutica... Read More
Raymond James analyst Rahul Sarugaser delivered an update to clients on Cardiol Therapeutics (Cardio... Read More
A delay in commercialization is cause for a lowering of the price target for Cardiol Therapeutics (C... Read More